CD59 Antibody (H-7): sc-133170

CD59 Antibody (H-7) is a mouse monoclonal IgG1 kappa light chain antibody that detects CD59 of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). CD59 (H-7) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CD59 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein predominantly expressed on leukocytes, vascular endothelial cells, various epithelial cells, and the placenta. CD59 functions to regulate the complement system, specifically by inhibiting the formation of the membrane attack complex (MAC), which is crucial for protecting host cells from lysis by complement proteins. CD59 achieves this by binding to the C8 and C9 components of the MAC, effectively preventing the lytic pore formation that could lead to cell damage. CD59 plays a role in T cell adhesion and activation, working alongside CD58, and may serve as a second ligand for CD2. The presence of two p53-responsive domains in the CD59 gene suggests a potential mechanism for protecting host cells from complement-mediated damage during inflammation, indicating that p53 could influence the susceptibility of tumor cells to complement lysis during chemotherapy. This multifaceted role of CD59 underscores its importance in immune regulation and potential therapeutic applications.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD59 Antibody (H-7) References:

1. Determination of CD59 protein in normal human serum by enzyme immunoassay, using octyl-glucoside detergent to release glycosyl-phosphatidylinositol-CD59 from lipid complex.  |  Landi, AP., et al. 2003. Immunol Lett. 90: 209-13. PMID: 14687727
2. Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis.  |  Lin, F., et al. 2004. J Immunol. 172: 2636-42. PMID: 14764738
3. Critical protection from renal ischemia reperfusion injury by CD55 and CD59.  |  Yamada, K., et al. 2004. J Immunol. 172: 3869-75. PMID: 15004194
4. Heterogeneous expression of CD59 on human Purkinje cells.  |  Storstein, A., et al. 2004. Neurosci Lett. 362: 21-5. PMID: 15147772
5. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy.  |  Xu, C., et al. 2005. Prostate. 62: 224-32. PMID: 15389793
6. Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack.  |  Babiker, AA., et al. 2005. Prostate. 62: 105-14. PMID: 15389819
7. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes.  |  Qin, X., et al. 2004. Diabetes. 53: 2653-61. PMID: 15448097
8. Human CD59 is a receptor for the cholesterol-dependent cytolysin intermedilysin.  |  Giddings, KS., et al. 2004. Nat Struct Mol Biol. 11: 1173-8. PMID: 15543155
9. Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects.  |  Davies, CS., et al. 2005. Immunology. 114: 280-6. PMID: 15667573
10. The complement inhibitor CD59 regulates insulin secretion by modulating exocytotic events.  |  Krus, U., et al. 2014. Cell Metab. 19: 883-90. PMID: 24726385
11. CD59 is a potential biomarker of esophageal squamous cell carcinoma radioresistance by affecting DNA repair.  |  Zhou, Y., et al. 2018. Cell Death Dis. 9: 887. PMID: 30166523
12. Bispecific mAb2 Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab.  |  Stadlbauer, K., et al. 2022. Int J Mol Sci. 23: PMID: 35563599

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CD59 Antibody (H-7) has 11 citations in a variety of scientific publications.

Primary antibodies like Anti-CD59 Antibody (H-7) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CD59 Antibody (H-7) Specifications

Alternate Product Name: Protectin

Product Clone Name: H-7

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 26-110

Epitope Target: CD59

Epitope Species: human

Product Reactivity/Detection: CD59

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 11 citations in various scientific publications

Available Conjugates/Forms for CD59 Antibody (H-7): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin